[1] 刘延青, 崔健君. 实用疼痛学[M]. 北京: 人民卫生出版社, 2019: 1871. [2] 徐建国. 成人手术后疼痛处理专家共识[J]. 临床麻醉学杂志, 2017, 33(9): 911-917. [3] WOOD J N, YAN N, HUANG J, et al. Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine)[J]. J Gen Physiol, 2025, 157(4): e202513778. [4] AGULLÓ L, AGUADO I, MURIEL J, et al. Pharmacogenetic guided opioid therapy improves chronic pain outcomes and comorbid mental health: a randomized, double-blind, controlled study[J]. Int J Mol Sci, 2023, 24(13): 10754. [5] 朱云柯, 林琳, 廖虎, 等. 中国胸外科围手术期疼痛管理专家共识(2018版)[J]. 中国胸心血管外科临床杂志, 2018, 25(11): 921-928. [6] DEAL B, PHILLIPS K, CRELLI C, et al. RNA-seq reveals sex differences in gene expression during peripheral neuropathic inflammation and in pain relief from a COX-2 inhibiting theranostic nanoemulsion[J]. Int J Mol Sci, 2023, 24(11): 9163. [7] BIRKINSHAW H, FRIEDRICH C, COLE P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis[J]. Health Technol Assess, 2024, 28(62): 1-155. [8] KIM E, RAJI M A, WESTRA J, et al. Comparative effectiveness of pain control between opioids and gabapentinoids in older patients with chronic pain[J]. Pain,2024, 165(1): 144-152. [9] FINNERUP N B, KUNER R, JENSEN T S. Neuropathic pain: from mechanisms to treatment[J]. Physiol Rev, 2021, 101(1): 259-301. [10] JIANG W, ZHANG L X, TAN X Y, et al. Inflammation and histone modification in chronic pain[J]. Front Immunol,2023, 13: 1087648. [11] XIONG H Y, HENDRIX J, SCHABRUN S, et al. The role of the brain-derived neurotrophic factor in chronic pain: links to central sensitization and neuroinflammation[J]. Biomolecules, 2024, 14(1): 71. [12] CHEN L, JIANG J, DOU B, et al. Machine learning study of the extended drug-target interaction network informed by pain related voltage-gated sodium channels[J].Pain, 2023, 165(4): 908-921. [13] TECHAMEENA P, FENG X, ZHANG K, et al. The single-cell transcriptomic atlas iPain identifies senescence of nociceptors as a therapeutical target for chronic pain treatment[J]. Nat Commun, 2024, 15(1):8585. [14] XIN L, ZHU H, NIU S, et al. Pharmacodynamic characteristics and influencing factors of tapentadol for chronic pain relief under dose titration[J]. Front Pain Res: Lausanne, 2025, 5: 1474529. [15] SECONDULFO C, MAZZEO F, PASTORINO G M G, et al. Opioid and cannabinoid systems in pain: emerging molecular mechanisms and use in clinical practice, health, and fitness[J]. Int J Mol Sci, 2024, 25(17): 9407. [16] HAMEED M, PRASAD S, JAIN E, et al. Medical cannabis for chronic nonmalignant pain management[J]. Curr Pain Headache Rep, 2023, 27(4): 57-63. [17] JO H G, BAEK C Y, HWANG Y, et al. Pain relief, functional recovery, and chondroprotective effects of Angelica gigas nakai in osteoarthritis due to its anti-inflammatory property: an in vitro and in vivo study[J]. Nutrients, 2024, 16(15): 2435. [18] BOCCELLA S, DE FILIPPIS L, GIORGIO C, et al. Combination drug therapy for the management of chronic neuropathic pain[J]. Biomolecules, 2023, 13(12): 1802. [19] CHENG P F, HE Y, GE M M, et al. Targeting the main sources of reactive oxygen species production: possible therapeutic implications in chronic pain[J]. Curr Neuropharmacol, 2024, 22(12): 1960-1985. [20] BERTA T, STRONG J A, ZHANG J M, et al. Targeting dorsal root ganglia and primary sensory neurons for the treatment of chronic pain: an update[J]. Expert Opin Ther Targets, 2023, 27(8): 665-678. [21] MCILWAIN B. A structural atlas for pain relief[J]. Nat Struct Mol Biol, 2023, 30(7): 873. [22] ALSALOUM M, VASYLYEV D, WAXMAN S G. Targeting sodium channels - challenges for acute pain and the leap to chronic pain[J]. Nat Rev Neurol, 2025, 21(10): 567-576. [23] YANG J, XIE Y F, SMITH R, et al. Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain[J]. Pain, 2025, 166(3): 481-501. [24] VARADI G. Mechanism of analgesia by gabapentinoid drugs: involvement of modulation of synaptogenesis and trafficking of glutamate-gated ion channels[J]. J Pharmacol Exp Ther, 2024, 388(1): 121-133. [25] 李海婷, 吴小余, 曹春阳. 靶向酸敏感离子通道的毒素肽: 镇痛机制与生物合成开发[J]. 化学学报, 2025, 83(7): 755-772. [26] SZALLASI A. Targeting TRPV1 for cancer pain relief: can it work?[J]. Cancers, 2024, 16(3): 648. [27] WAN Y, ZHOU J, LI H. The role of mechanosensitive Piezo channels in chronic pain[J]. J Pain Res, 2024, 17: 4199-4212. [28] MELANCON K, PLIUSHCHEUSKAYA P, MEILER J, et al. Targeting ion channels with ultra-large library screening for hit discovery[J]. Front Mol Neurosci,2024, 16: 1336004. [29] KUETE C F, GRANJA-VAZQUEZ R, TRUONG V, et al. Profiling human iPSC-derived sensory neurons for analgesic drug screening using a multi-electrode array[J]. bioRxiv, 2024. DOI: 10.1101/2024.11.18.623405. [30] DEY S, BHATTACHARYA T, SINHA S. Pain relief: unique derivatives of ibogaine alleviate both acute and chronic pain symptoms[J]. Physiology, 2024, 39(S1): 1689. [31] XIA S, QIN X, WANG Y. DMH1-loaded peptide nanomicelles restore myelin and attenuate neuroinflammation in trigeminal neuralgiavia CCL5 suppression[J]. Front Pharmacol, 2025, 16: 1590624. [32] BECKER J, EFFRAIM P R, DIB-HAJJ S, et al. Lessons learned in translating pain knowledge into practice[J]. Pain Rep, 2023, 8(6): e1100. [33] JU J, LI Z, JIA X, et al. Interleukin-18 in chronic pain: focus on pathogenic mechanisms and potential therapeutic targets[J]. Pharmacol Res, 2024, 201: 107089. [34] MORIOKA N. Drug developmental strategies based on functional analysis of pain-regulating molecules in astrocytes under chronic pain[J].Nihon Yakurigaku Zasshi, 2024, 159(6): 363-366. [35] SOLIMAN N, KERSEBAUM D, LAWN T, et al. Improving neuropathic pain treatment - by rigorous stratification from bench to bedside[J]. J Neurochem,2024, 168(11): 3699-3714. [36] MA L, SUN D, WEN S, et al. PSD-95 protein: a promising therapeutic target in chronic pain[J]. Mol Neurobiol,2025, 62(3): 3361-3375. [37] CUI M, JI R, SONG L, et al. Neuronal and molecular mechanisms underlying chronic pain and depression comorbidity in the paraventricular thalamus[J]. J Neurosci, 2024, 44(13): e1752232024. [38] RAJI M A, SHAH R, WESTRA J R, et al. Central nervous system active medication use in medicare enrollees receiving home health care: association with chronic pain and anxiety level[J]. Pain, 2025, 166(1): 123-129. [39] 兰艳艳, 庞莉娜, 黄秋玲, 等. 基于脊髓背角5-HT1AR途径探讨腕踝针治疗紫杉醇诱导神经性疼痛小鼠的镇痛机制[J]. 中华中医药杂志, 2025, 40(3): 1081-1085. [40] 杜志强. 基于fMRI技术探讨温针治疗膝骨关节炎中枢镇痛机制的临床研究[C]//中国生命关怀协会. 关爱生命大讲堂之生命关怀与智慧康养系列学术研讨会论文集上-临床心理关怀与医院人文建设的融合专题. 北京, 2025: 500-502. [41] JI R R, CHAMESSIAN A, ZHANG Y Q. Pain regulation by non-neuronal cells and inflammation[J]. Science, 2016, 354(6312): 572-577. [42] JI R R, XU Z Z, GAO Y J. Emerging targets in neuroinflammation-driven chronic pain[J]. Nat Rev Drug Discov, 2014, 13(7): 533-548. [43] CHIU I M. Infection, pain, and itch[J]. Neurosci Bull, 2018, 34(1): 109-119. [44] GRACE P M, HUTCHINSON M R, MAIER S F,et al. Pathological pain and the neuroimmune interface[J]. Nat Rev Immunol, 2014, 14(4): 217-231. [45] MURPHY S F, SCHAEFFER A J, THUMBIKAT P. Immune mediators of chronic pelvic pain syndrome[J]. Nat Rev Urol, 2014, 11(5): 259-269. [46] TSUDA M. Modulation of pain and itch by spinal glia[J]. Neurosci Bull, 2018, 34(1): 178-185. [47] DO NASCIMENTO A M, MARQUES R B, ROLDÃO A P, et al. Exploring protein-protein interactions for the development of new analgesics[J]. Sci Signal, 2024, 17(857): eadn4694. [48] QU X, DU G, HU J, et al. Graph-DTI: a new model for drug-target interaction prediction based on heterogenous network graph embedding[J]. Curr Comput Aided Drug Des, 2024, 20(6): 1013-1024. [49] MOHAPATRA M, SAHU C, MOHAPATRA S. Trends of artificial intelligence (AI) use in drug targets, discovery and development: current status and future perspectives[J]. Curr Drug Targets, 2025, 26(4): 221-242. [50] MOHANKUMAR N, REDDY NARANI S, ASHA S, et al. Advancing chronic pain relief cloud-based remote management with machine learning in healthcare[J]. Indones J Electr Eng Comput Sci, 2025, 37(2): 1042-1052. [51] MEIER T A, REFAHI M S, HEARNE G, et al. The role and applications of artificial intelligence in the treatment of chronic pain[J]. Curr Pain Headache Rep, 2024, 28(8): 769-784. |